Global Chronic Obstructive Pulmonary Disorder

Chronic Obstructive Pulmonary Disorder Comprehensive Study by Type (Chronic Bronchitis, Emphysema), Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Medication Type (Bronchodilators, Inhaled Steroids, Combination Inhalers, Oral Steroids, Phosphodiesterase-4 inhibitors, Theophylline, Antibiotics), Treatment Type (Medication, Surgery), Diagnosis (Lung (Pulmonary) Function Tests, Chest X-Ray, CT Scan, Arterial Blood Gas Analysis, Laboratory Tests) Players and Region - Global Market Outlook to 2028

Chronic Obstructive Pulmonary Disorder Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Chronic Obstructive Pulmonary Disorder Market Scope?
Chronic obstructive pulmonary disease is basically a chronic inflammatory lung disease that hereby causes obstructed airflow from the lungs. Symptoms include difficulty breathing, coughing, mucus (sputum) build-up, and wheezing. It is usually caused by long-term exposure to irritating gases or particles, most often from cigarette smoke. People with COPD are at increased risk of developing heart disease, lung cancer, and a variety of other conditions. Emphysema and chronic bronchitis are the two most common conditions that contribute to COPD. These two conditions usually occur together and can vary in severity in people with COPD. Chronic bronchitis is inflammation of the lining of the bronchi that carry air to and from the air sacs (alveoli) of the lungs. It is characterized by the daily production of cough and mucus (sputum). Emphysema is a condition in which the alveoli at the end of the smallest airways (bronchioles) in the lungs are destroyed from harmful exposure to cigarette smoke and other irritating gases and particles. Although COPD is a progressive disease that gets worse over time, COPD is treatable. With proper treatment, most people with COPD can achieve good symptom control and quality of life, and a lower risk of other related conditions. In 2016, COPD was the third leading cause of death worldwide, with around 3 million deaths that year. In the United States, the state of West Virginia had the highest COPD prevalence in 2017, with nearly 14 percent of adults in the state being diagnosed with the disease. By comparison, only 3.4 percent of Hawaiian adults were diagnosed with COPD. The lowest rate in the US is higher among certain populations. 11 percent of Native American / Alaskan people have been diagnosed, compared with just 3 percent of Hispanics.

Influencing Trend:
Advanced Healthcare Infrastructure, Demand For Home Care Therapeutics Devices and Rising Awareness among Population about the Use of Generic Drug

Market Growth Drivers:
An Increase in Incidence and Prevalence of Asthma and COPD, Increasing Consumption of Tobacco among Youth Population, High Disposable Income, And Lifestyle Changes and Increasing Automotive and Industrial Exhaust Gases

Challenges:
Increasing Problem Associated With Patent Expiry

Restraints:
High Cost of the COPD Treatment and The Dearth of Awareness and Knowledge among Population about COPD Symptoms and Indications

Opportunities:
Increasing R&D Investment by Government and Major Players and The Rise in the Number of Initiatives Undertaken By Government and Non-Government Organizations

The Chronic Obstructive Pulmonary Disorder market study is being classified by Type (Chronic Bronchitis and Emphysema), by Application and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analysts at AMA predicts that Players from European will contribute to the maximum growth of Global Chronic Obstructive Pulmonary Disorder market throughout the predicted period.

AstraZeneca (United Kingdom), Boehringer Ingelheim (Germany), GlaxoSmithKline plc (United Kingdom), Novartis AG (Switzerland), Teva Pharmaceuticals (Israel), Ache Laboratorios Farmaceuticos (Brazil), Sunovion Pharmaceuticals Inc. (United States), CHIESI Farmaceutici S.p.A. (Italy), Almirall (Spain), Aquinox Pharmaceuticals (United States), Orion Corporation (Finland), Mylan N.V. (United States) and Ario Pharma (United Kingdom) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Odan Laboratories (Canada), Astellas Pharma (Japan) and BioMarck Pharmaceuticals (United States).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Chronic Obstructive Pulmonary Disorder market by Type, Application and Region.

On the basis of geography, the market of Chronic Obstructive Pulmonary Disorder has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Influencers and their Development Strategies
In 2019, CHIESI Farmaceutici S.p.A. an exclusive global license agreement with TiumBio, a private clinical-stage biotech company based in South Korea. TiumBio specializes in researching innovative drugs for rare diseases. This agreement aims to develop innovative molecules for the treatment of respiratory diseases.
In 2019, AstraZeneca, an Anglo-Swedish multinational pharmaceutical company, announced the approval of Breztri Aerosphere, a pressurized metered-dose inhaler with integrated triple combination therapy for patients with moderate to severe COPD in Japan.
Various regulators like the European Commission, the FDA, the Ministry of Health, Labor, and Social Affairs (MHLW), and a cabinet-level ministry of the Japanese government, had thereby approved the usage of combination drugs for treating COPD. In April 2019, the FDA approved combination therapy for the maintenance of COPD. A combination of a long-acting muscarinic antagonist (LAMA), aclidinium bromide (400 µg) and a long-acting beta-agonist (LABA), formoterol fumarate (12 µg), has been approved by the FDA for the maintenance and treatment of chronic obstructive pulmonary disease.

Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Chronic Obstructive Pulmonary Disorder Treatment, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry

Chronic Obstructive Pulmonary Disorder Market Study: Important Years
AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Major Highlights of Market Study

Demand Determinants: Identifying top-notch application and business segments that seek high growth potentials in Chronic Obstructive Pulmonary Disorder Market.

Key Strategic Developments: To target untapped regions more aggressively by focusing on product/service developments, innovation and R & D, new launches, Merger & acquisitions, JVs & partnerships.

Forces & Market Dynamics: Growth drivers, restraints & opportunities available in Chronic Obstructive Pulmonary Disorder industry is examined with reference relevant market sectors and sub-sectors.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also includes significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets, To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Chronic Bronchitis
  • Emphysema
By Application
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
By Medication Type
  • Bronchodilators
  • Inhaled Steroids
  • Combination Inhalers
  • Oral Steroids
  • Phosphodiesterase-4 inhibitors
  • Theophylline
  • Antibiotics

By Treatment Type
  • Medication
  • Surgery

By Diagnosis
  • Lung (Pulmonary) Function Tests
  • Chest X-Ray
  • CT Scan
  • Arterial Blood Gas Analysis
  • Laboratory Tests

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. An Increase in Incidence and Prevalence of Asthma and COPD
      • 3.2.2. Increasing Consumption of Tobacco among Youth Population
      • 3.2.3. High Disposable Income, And Lifestyle Changes
      • 3.2.4. Increasing Automotive and Industrial Exhaust Gases
    • 3.3. Market Challenges
      • 3.3.1. Increasing Problem Associated With Patent Expiry
    • 3.4. Market Trends
      • 3.4.1. Advanced Healthcare Infrastructure
      • 3.4.2. Demand For Home Care Therapeutics Devices
      • 3.4.3. Rising Awareness among Population about the Use of Generic Drug
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Chronic Obstructive Pulmonary Disorder, by Type, Application, Medication Type, Treatment Type, Diagnosis and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Chronic Obstructive Pulmonary Disorder (Value)
      • 5.2.1. Global Chronic Obstructive Pulmonary Disorder by: Type (Value)
        • 5.2.1.1. Chronic Bronchitis
        • 5.2.1.2. Emphysema
      • 5.2.2. Global Chronic Obstructive Pulmonary Disorder by: Application (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Retail Pharmacies
        • 5.2.2.3. Online Pharmacies
      • 5.2.3. Global Chronic Obstructive Pulmonary Disorder by: Medication Type (Value)
        • 5.2.3.1. Bronchodilators
        • 5.2.3.2. Inhaled Steroids
        • 5.2.3.3. Combination Inhalers
        • 5.2.3.4. Oral Steroids
        • 5.2.3.5. Phosphodiesterase-4 inhibitors
        • 5.2.3.6. Theophylline
        • 5.2.3.7. Antibiotics
      • 5.2.4. Global Chronic Obstructive Pulmonary Disorder by: Treatment Type (Value)
        • 5.2.4.1. Medication
        • 5.2.4.2. Surgery
      • 5.2.5. Global Chronic Obstructive Pulmonary Disorder by: Diagnosis (Value)
        • 5.2.5.1. Lung (Pulmonary) Function Tests
        • 5.2.5.2. Chest X-Ray
        • 5.2.5.3. CT Scan
        • 5.2.5.4. Arterial Blood Gas Analysis
        • 5.2.5.5. Laboratory Tests
      • 5.2.6. Global Chronic Obstructive Pulmonary Disorder Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Chronic Obstructive Pulmonary Disorder: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Boehringer Ingelheim (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Teva Pharmaceuticals (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Ache Laboratorios Farmaceuticos (Brazil)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sunovion Pharmaceuticals Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. CHIESI Farmaceutici S.p.A. (Italy)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Almirall (Spain)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Aquinox Pharmaceuticals (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Orion Corporation (Finland)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Mylan N.V. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Ario Pharma (United Kingdom)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Chronic Obstructive Pulmonary Disorder Sale, by Type, Application, Medication Type, Treatment Type, Diagnosis and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Chronic Obstructive Pulmonary Disorder (Value)
      • 7.2.1. Global Chronic Obstructive Pulmonary Disorder by: Type (Value)
        • 7.2.1.1. Chronic Bronchitis
        • 7.2.1.2. Emphysema
      • 7.2.2. Global Chronic Obstructive Pulmonary Disorder by: Application (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Retail Pharmacies
        • 7.2.2.3. Online Pharmacies
      • 7.2.3. Global Chronic Obstructive Pulmonary Disorder by: Medication Type (Value)
        • 7.2.3.1. Bronchodilators
        • 7.2.3.2. Inhaled Steroids
        • 7.2.3.3. Combination Inhalers
        • 7.2.3.4. Oral Steroids
        • 7.2.3.5. Phosphodiesterase-4 inhibitors
        • 7.2.3.6. Theophylline
        • 7.2.3.7. Antibiotics
      • 7.2.4. Global Chronic Obstructive Pulmonary Disorder by: Treatment Type (Value)
        • 7.2.4.1. Medication
        • 7.2.4.2. Surgery
      • 7.2.5. Global Chronic Obstructive Pulmonary Disorder by: Diagnosis (Value)
        • 7.2.5.1. Lung (Pulmonary) Function Tests
        • 7.2.5.2. Chest X-Ray
        • 7.2.5.3. CT Scan
        • 7.2.5.4. Arterial Blood Gas Analysis
        • 7.2.5.5. Laboratory Tests
      • 7.2.6. Global Chronic Obstructive Pulmonary Disorder Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Chronic Obstructive Pulmonary Disorder: by Type(USD Million)
  • Table 2. Chronic Obstructive Pulmonary Disorder Chronic Bronchitis , by Region USD Million (2017-2022)
  • Table 3. Chronic Obstructive Pulmonary Disorder Emphysema , by Region USD Million (2017-2022)
  • Table 4. Chronic Obstructive Pulmonary Disorder: by Application(USD Million)
  • Table 5. Chronic Obstructive Pulmonary Disorder Hospital Pharmacies , by Region USD Million (2017-2022)
  • Table 6. Chronic Obstructive Pulmonary Disorder Retail Pharmacies , by Region USD Million (2017-2022)
  • Table 7. Chronic Obstructive Pulmonary Disorder Online Pharmacies , by Region USD Million (2017-2022)
  • Table 8. Chronic Obstructive Pulmonary Disorder: by Medication Type(USD Million)
  • Table 9. Chronic Obstructive Pulmonary Disorder Bronchodilators , by Region USD Million (2017-2022)
  • Table 10. Chronic Obstructive Pulmonary Disorder Inhaled Steroids , by Region USD Million (2017-2022)
  • Table 11. Chronic Obstructive Pulmonary Disorder Combination Inhalers , by Region USD Million (2017-2022)
  • Table 12. Chronic Obstructive Pulmonary Disorder Oral Steroids , by Region USD Million (2017-2022)
  • Table 13. Chronic Obstructive Pulmonary Disorder Phosphodiesterase-4 inhibitors , by Region USD Million (2017-2022)
  • Table 14. Chronic Obstructive Pulmonary Disorder Theophylline , by Region USD Million (2017-2022)
  • Table 15. Chronic Obstructive Pulmonary Disorder Antibiotics , by Region USD Million (2017-2022)
  • Table 16. Chronic Obstructive Pulmonary Disorder: by Treatment Type(USD Million)
  • Table 17. Chronic Obstructive Pulmonary Disorder Medication , by Region USD Million (2017-2022)
  • Table 18. Chronic Obstructive Pulmonary Disorder Surgery , by Region USD Million (2017-2022)
  • Table 19. Chronic Obstructive Pulmonary Disorder: by Diagnosis(USD Million)
  • Table 20. Chronic Obstructive Pulmonary Disorder Lung (Pulmonary) Function Tests , by Region USD Million (2017-2022)
  • Table 21. Chronic Obstructive Pulmonary Disorder Chest X-Ray , by Region USD Million (2017-2022)
  • Table 22. Chronic Obstructive Pulmonary Disorder CT Scan , by Region USD Million (2017-2022)
  • Table 23. Chronic Obstructive Pulmonary Disorder Arterial Blood Gas Analysis , by Region USD Million (2017-2022)
  • Table 24. Chronic Obstructive Pulmonary Disorder Laboratory Tests , by Region USD Million (2017-2022)
  • Table 25. South America Chronic Obstructive Pulmonary Disorder, by Country USD Million (2017-2022)
  • Table 26. South America Chronic Obstructive Pulmonary Disorder, by Type USD Million (2017-2022)
  • Table 27. South America Chronic Obstructive Pulmonary Disorder, by Application USD Million (2017-2022)
  • Table 28. South America Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2017-2022)
  • Table 29. South America Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2017-2022)
  • Table 30. South America Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2017-2022)
  • Table 31. Brazil Chronic Obstructive Pulmonary Disorder, by Type USD Million (2017-2022)
  • Table 32. Brazil Chronic Obstructive Pulmonary Disorder, by Application USD Million (2017-2022)
  • Table 33. Brazil Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2017-2022)
  • Table 34. Brazil Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2017-2022)
  • Table 35. Brazil Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2017-2022)
  • Table 36. Argentina Chronic Obstructive Pulmonary Disorder, by Type USD Million (2017-2022)
  • Table 37. Argentina Chronic Obstructive Pulmonary Disorder, by Application USD Million (2017-2022)
  • Table 38. Argentina Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2017-2022)
  • Table 39. Argentina Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2017-2022)
  • Table 40. Argentina Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2017-2022)
  • Table 41. Rest of South America Chronic Obstructive Pulmonary Disorder, by Type USD Million (2017-2022)
  • Table 42. Rest of South America Chronic Obstructive Pulmonary Disorder, by Application USD Million (2017-2022)
  • Table 43. Rest of South America Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2017-2022)
  • Table 44. Rest of South America Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2017-2022)
  • Table 45. Rest of South America Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2017-2022)
  • Table 46. Asia Pacific Chronic Obstructive Pulmonary Disorder, by Country USD Million (2017-2022)
  • Table 47. Asia Pacific Chronic Obstructive Pulmonary Disorder, by Type USD Million (2017-2022)
  • Table 48. Asia Pacific Chronic Obstructive Pulmonary Disorder, by Application USD Million (2017-2022)
  • Table 49. Asia Pacific Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2017-2022)
  • Table 50. Asia Pacific Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2017-2022)
  • Table 51. Asia Pacific Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2017-2022)
  • Table 52. China Chronic Obstructive Pulmonary Disorder, by Type USD Million (2017-2022)
  • Table 53. China Chronic Obstructive Pulmonary Disorder, by Application USD Million (2017-2022)
  • Table 54. China Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2017-2022)
  • Table 55. China Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2017-2022)
  • Table 56. China Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2017-2022)
  • Table 57. Japan Chronic Obstructive Pulmonary Disorder, by Type USD Million (2017-2022)
  • Table 58. Japan Chronic Obstructive Pulmonary Disorder, by Application USD Million (2017-2022)
  • Table 59. Japan Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2017-2022)
  • Table 60. Japan Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2017-2022)
  • Table 61. Japan Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2017-2022)
  • Table 62. India Chronic Obstructive Pulmonary Disorder, by Type USD Million (2017-2022)
  • Table 63. India Chronic Obstructive Pulmonary Disorder, by Application USD Million (2017-2022)
  • Table 64. India Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2017-2022)
  • Table 65. India Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2017-2022)
  • Table 66. India Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2017-2022)
  • Table 67. South Korea Chronic Obstructive Pulmonary Disorder, by Type USD Million (2017-2022)
  • Table 68. South Korea Chronic Obstructive Pulmonary Disorder, by Application USD Million (2017-2022)
  • Table 69. South Korea Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2017-2022)
  • Table 70. South Korea Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2017-2022)
  • Table 71. South Korea Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2017-2022)
  • Table 72. Taiwan Chronic Obstructive Pulmonary Disorder, by Type USD Million (2017-2022)
  • Table 73. Taiwan Chronic Obstructive Pulmonary Disorder, by Application USD Million (2017-2022)
  • Table 74. Taiwan Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2017-2022)
  • Table 75. Taiwan Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2017-2022)
  • Table 76. Taiwan Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2017-2022)
  • Table 77. Australia Chronic Obstructive Pulmonary Disorder, by Type USD Million (2017-2022)
  • Table 78. Australia Chronic Obstructive Pulmonary Disorder, by Application USD Million (2017-2022)
  • Table 79. Australia Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2017-2022)
  • Table 80. Australia Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2017-2022)
  • Table 81. Australia Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2017-2022)
  • Table 82. Rest of Asia-Pacific Chronic Obstructive Pulmonary Disorder, by Type USD Million (2017-2022)
  • Table 83. Rest of Asia-Pacific Chronic Obstructive Pulmonary Disorder, by Application USD Million (2017-2022)
  • Table 84. Rest of Asia-Pacific Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2017-2022)
  • Table 85. Rest of Asia-Pacific Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2017-2022)
  • Table 86. Rest of Asia-Pacific Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2017-2022)
  • Table 87. Europe Chronic Obstructive Pulmonary Disorder, by Country USD Million (2017-2022)
  • Table 88. Europe Chronic Obstructive Pulmonary Disorder, by Type USD Million (2017-2022)
  • Table 89. Europe Chronic Obstructive Pulmonary Disorder, by Application USD Million (2017-2022)
  • Table 90. Europe Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2017-2022)
  • Table 91. Europe Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2017-2022)
  • Table 92. Europe Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2017-2022)
  • Table 93. Germany Chronic Obstructive Pulmonary Disorder, by Type USD Million (2017-2022)
  • Table 94. Germany Chronic Obstructive Pulmonary Disorder, by Application USD Million (2017-2022)
  • Table 95. Germany Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2017-2022)
  • Table 96. Germany Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2017-2022)
  • Table 97. Germany Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2017-2022)
  • Table 98. France Chronic Obstructive Pulmonary Disorder, by Type USD Million (2017-2022)
  • Table 99. France Chronic Obstructive Pulmonary Disorder, by Application USD Million (2017-2022)
  • Table 100. France Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2017-2022)
  • Table 101. France Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2017-2022)
  • Table 102. France Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2017-2022)
  • Table 103. Italy Chronic Obstructive Pulmonary Disorder, by Type USD Million (2017-2022)
  • Table 104. Italy Chronic Obstructive Pulmonary Disorder, by Application USD Million (2017-2022)
  • Table 105. Italy Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2017-2022)
  • Table 106. Italy Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2017-2022)
  • Table 107. Italy Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2017-2022)
  • Table 108. United Kingdom Chronic Obstructive Pulmonary Disorder, by Type USD Million (2017-2022)
  • Table 109. United Kingdom Chronic Obstructive Pulmonary Disorder, by Application USD Million (2017-2022)
  • Table 110. United Kingdom Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2017-2022)
  • Table 111. United Kingdom Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2017-2022)
  • Table 112. United Kingdom Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2017-2022)
  • Table 113. Netherlands Chronic Obstructive Pulmonary Disorder, by Type USD Million (2017-2022)
  • Table 114. Netherlands Chronic Obstructive Pulmonary Disorder, by Application USD Million (2017-2022)
  • Table 115. Netherlands Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2017-2022)
  • Table 116. Netherlands Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2017-2022)
  • Table 117. Netherlands Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2017-2022)
  • Table 118. Rest of Europe Chronic Obstructive Pulmonary Disorder, by Type USD Million (2017-2022)
  • Table 119. Rest of Europe Chronic Obstructive Pulmonary Disorder, by Application USD Million (2017-2022)
  • Table 120. Rest of Europe Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2017-2022)
  • Table 121. Rest of Europe Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2017-2022)
  • Table 122. Rest of Europe Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2017-2022)
  • Table 123. MEA Chronic Obstructive Pulmonary Disorder, by Country USD Million (2017-2022)
  • Table 124. MEA Chronic Obstructive Pulmonary Disorder, by Type USD Million (2017-2022)
  • Table 125. MEA Chronic Obstructive Pulmonary Disorder, by Application USD Million (2017-2022)
  • Table 126. MEA Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2017-2022)
  • Table 127. MEA Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2017-2022)
  • Table 128. MEA Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2017-2022)
  • Table 129. Middle East Chronic Obstructive Pulmonary Disorder, by Type USD Million (2017-2022)
  • Table 130. Middle East Chronic Obstructive Pulmonary Disorder, by Application USD Million (2017-2022)
  • Table 131. Middle East Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2017-2022)
  • Table 132. Middle East Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2017-2022)
  • Table 133. Middle East Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2017-2022)
  • Table 134. Africa Chronic Obstructive Pulmonary Disorder, by Type USD Million (2017-2022)
  • Table 135. Africa Chronic Obstructive Pulmonary Disorder, by Application USD Million (2017-2022)
  • Table 136. Africa Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2017-2022)
  • Table 137. Africa Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2017-2022)
  • Table 138. Africa Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2017-2022)
  • Table 139. North America Chronic Obstructive Pulmonary Disorder, by Country USD Million (2017-2022)
  • Table 140. North America Chronic Obstructive Pulmonary Disorder, by Type USD Million (2017-2022)
  • Table 141. North America Chronic Obstructive Pulmonary Disorder, by Application USD Million (2017-2022)
  • Table 142. North America Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2017-2022)
  • Table 143. North America Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2017-2022)
  • Table 144. North America Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2017-2022)
  • Table 145. United States Chronic Obstructive Pulmonary Disorder, by Type USD Million (2017-2022)
  • Table 146. United States Chronic Obstructive Pulmonary Disorder, by Application USD Million (2017-2022)
  • Table 147. United States Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2017-2022)
  • Table 148. United States Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2017-2022)
  • Table 149. United States Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2017-2022)
  • Table 150. Canada Chronic Obstructive Pulmonary Disorder, by Type USD Million (2017-2022)
  • Table 151. Canada Chronic Obstructive Pulmonary Disorder, by Application USD Million (2017-2022)
  • Table 152. Canada Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2017-2022)
  • Table 153. Canada Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2017-2022)
  • Table 154. Canada Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2017-2022)
  • Table 155. Mexico Chronic Obstructive Pulmonary Disorder, by Type USD Million (2017-2022)
  • Table 156. Mexico Chronic Obstructive Pulmonary Disorder, by Application USD Million (2017-2022)
  • Table 157. Mexico Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2017-2022)
  • Table 158. Mexico Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2017-2022)
  • Table 159. Mexico Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2017-2022)
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Company Basic Information, Sales Area and Its Competitors
  • Table 173. Chronic Obstructive Pulmonary Disorder: by Type(USD Million)
  • Table 174. Chronic Obstructive Pulmonary Disorder Chronic Bronchitis , by Region USD Million (2023-2028)
  • Table 175. Chronic Obstructive Pulmonary Disorder Emphysema , by Region USD Million (2023-2028)
  • Table 176. Chronic Obstructive Pulmonary Disorder: by Application(USD Million)
  • Table 177. Chronic Obstructive Pulmonary Disorder Hospital Pharmacies , by Region USD Million (2023-2028)
  • Table 178. Chronic Obstructive Pulmonary Disorder Retail Pharmacies , by Region USD Million (2023-2028)
  • Table 179. Chronic Obstructive Pulmonary Disorder Online Pharmacies , by Region USD Million (2023-2028)
  • Table 180. Chronic Obstructive Pulmonary Disorder: by Medication Type(USD Million)
  • Table 181. Chronic Obstructive Pulmonary Disorder Bronchodilators , by Region USD Million (2023-2028)
  • Table 182. Chronic Obstructive Pulmonary Disorder Inhaled Steroids , by Region USD Million (2023-2028)
  • Table 183. Chronic Obstructive Pulmonary Disorder Combination Inhalers , by Region USD Million (2023-2028)
  • Table 184. Chronic Obstructive Pulmonary Disorder Oral Steroids , by Region USD Million (2023-2028)
  • Table 185. Chronic Obstructive Pulmonary Disorder Phosphodiesterase-4 inhibitors , by Region USD Million (2023-2028)
  • Table 186. Chronic Obstructive Pulmonary Disorder Theophylline , by Region USD Million (2023-2028)
  • Table 187. Chronic Obstructive Pulmonary Disorder Antibiotics , by Region USD Million (2023-2028)
  • Table 188. Chronic Obstructive Pulmonary Disorder: by Treatment Type(USD Million)
  • Table 189. Chronic Obstructive Pulmonary Disorder Medication , by Region USD Million (2023-2028)
  • Table 190. Chronic Obstructive Pulmonary Disorder Surgery , by Region USD Million (2023-2028)
  • Table 191. Chronic Obstructive Pulmonary Disorder: by Diagnosis(USD Million)
  • Table 192. Chronic Obstructive Pulmonary Disorder Lung (Pulmonary) Function Tests , by Region USD Million (2023-2028)
  • Table 193. Chronic Obstructive Pulmonary Disorder Chest X-Ray , by Region USD Million (2023-2028)
  • Table 194. Chronic Obstructive Pulmonary Disorder CT Scan , by Region USD Million (2023-2028)
  • Table 195. Chronic Obstructive Pulmonary Disorder Arterial Blood Gas Analysis , by Region USD Million (2023-2028)
  • Table 196. Chronic Obstructive Pulmonary Disorder Laboratory Tests , by Region USD Million (2023-2028)
  • Table 197. South America Chronic Obstructive Pulmonary Disorder, by Country USD Million (2023-2028)
  • Table 198. South America Chronic Obstructive Pulmonary Disorder, by Type USD Million (2023-2028)
  • Table 199. South America Chronic Obstructive Pulmonary Disorder, by Application USD Million (2023-2028)
  • Table 200. South America Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2023-2028)
  • Table 201. South America Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2023-2028)
  • Table 202. South America Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2023-2028)
  • Table 203. Brazil Chronic Obstructive Pulmonary Disorder, by Type USD Million (2023-2028)
  • Table 204. Brazil Chronic Obstructive Pulmonary Disorder, by Application USD Million (2023-2028)
  • Table 205. Brazil Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2023-2028)
  • Table 206. Brazil Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2023-2028)
  • Table 207. Brazil Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2023-2028)
  • Table 208. Argentina Chronic Obstructive Pulmonary Disorder, by Type USD Million (2023-2028)
  • Table 209. Argentina Chronic Obstructive Pulmonary Disorder, by Application USD Million (2023-2028)
  • Table 210. Argentina Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2023-2028)
  • Table 211. Argentina Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2023-2028)
  • Table 212. Argentina Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2023-2028)
  • Table 213. Rest of South America Chronic Obstructive Pulmonary Disorder, by Type USD Million (2023-2028)
  • Table 214. Rest of South America Chronic Obstructive Pulmonary Disorder, by Application USD Million (2023-2028)
  • Table 215. Rest of South America Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2023-2028)
  • Table 216. Rest of South America Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2023-2028)
  • Table 217. Rest of South America Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2023-2028)
  • Table 218. Asia Pacific Chronic Obstructive Pulmonary Disorder, by Country USD Million (2023-2028)
  • Table 219. Asia Pacific Chronic Obstructive Pulmonary Disorder, by Type USD Million (2023-2028)
  • Table 220. Asia Pacific Chronic Obstructive Pulmonary Disorder, by Application USD Million (2023-2028)
  • Table 221. Asia Pacific Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2023-2028)
  • Table 222. Asia Pacific Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2023-2028)
  • Table 223. Asia Pacific Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2023-2028)
  • Table 224. China Chronic Obstructive Pulmonary Disorder, by Type USD Million (2023-2028)
  • Table 225. China Chronic Obstructive Pulmonary Disorder, by Application USD Million (2023-2028)
  • Table 226. China Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2023-2028)
  • Table 227. China Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2023-2028)
  • Table 228. China Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2023-2028)
  • Table 229. Japan Chronic Obstructive Pulmonary Disorder, by Type USD Million (2023-2028)
  • Table 230. Japan Chronic Obstructive Pulmonary Disorder, by Application USD Million (2023-2028)
  • Table 231. Japan Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2023-2028)
  • Table 232. Japan Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2023-2028)
  • Table 233. Japan Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2023-2028)
  • Table 234. India Chronic Obstructive Pulmonary Disorder, by Type USD Million (2023-2028)
  • Table 235. India Chronic Obstructive Pulmonary Disorder, by Application USD Million (2023-2028)
  • Table 236. India Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2023-2028)
  • Table 237. India Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2023-2028)
  • Table 238. India Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2023-2028)
  • Table 239. South Korea Chronic Obstructive Pulmonary Disorder, by Type USD Million (2023-2028)
  • Table 240. South Korea Chronic Obstructive Pulmonary Disorder, by Application USD Million (2023-2028)
  • Table 241. South Korea Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2023-2028)
  • Table 242. South Korea Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2023-2028)
  • Table 243. South Korea Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2023-2028)
  • Table 244. Taiwan Chronic Obstructive Pulmonary Disorder, by Type USD Million (2023-2028)
  • Table 245. Taiwan Chronic Obstructive Pulmonary Disorder, by Application USD Million (2023-2028)
  • Table 246. Taiwan Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2023-2028)
  • Table 247. Taiwan Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2023-2028)
  • Table 248. Taiwan Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2023-2028)
  • Table 249. Australia Chronic Obstructive Pulmonary Disorder, by Type USD Million (2023-2028)
  • Table 250. Australia Chronic Obstructive Pulmonary Disorder, by Application USD Million (2023-2028)
  • Table 251. Australia Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2023-2028)
  • Table 252. Australia Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2023-2028)
  • Table 253. Australia Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2023-2028)
  • Table 254. Rest of Asia-Pacific Chronic Obstructive Pulmonary Disorder, by Type USD Million (2023-2028)
  • Table 255. Rest of Asia-Pacific Chronic Obstructive Pulmonary Disorder, by Application USD Million (2023-2028)
  • Table 256. Rest of Asia-Pacific Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2023-2028)
  • Table 257. Rest of Asia-Pacific Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2023-2028)
  • Table 258. Rest of Asia-Pacific Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2023-2028)
  • Table 259. Europe Chronic Obstructive Pulmonary Disorder, by Country USD Million (2023-2028)
  • Table 260. Europe Chronic Obstructive Pulmonary Disorder, by Type USD Million (2023-2028)
  • Table 261. Europe Chronic Obstructive Pulmonary Disorder, by Application USD Million (2023-2028)
  • Table 262. Europe Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2023-2028)
  • Table 263. Europe Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2023-2028)
  • Table 264. Europe Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2023-2028)
  • Table 265. Germany Chronic Obstructive Pulmonary Disorder, by Type USD Million (2023-2028)
  • Table 266. Germany Chronic Obstructive Pulmonary Disorder, by Application USD Million (2023-2028)
  • Table 267. Germany Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2023-2028)
  • Table 268. Germany Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2023-2028)
  • Table 269. Germany Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2023-2028)
  • Table 270. France Chronic Obstructive Pulmonary Disorder, by Type USD Million (2023-2028)
  • Table 271. France Chronic Obstructive Pulmonary Disorder, by Application USD Million (2023-2028)
  • Table 272. France Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2023-2028)
  • Table 273. France Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2023-2028)
  • Table 274. France Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2023-2028)
  • Table 275. Italy Chronic Obstructive Pulmonary Disorder, by Type USD Million (2023-2028)
  • Table 276. Italy Chronic Obstructive Pulmonary Disorder, by Application USD Million (2023-2028)
  • Table 277. Italy Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2023-2028)
  • Table 278. Italy Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2023-2028)
  • Table 279. Italy Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2023-2028)
  • Table 280. United Kingdom Chronic Obstructive Pulmonary Disorder, by Type USD Million (2023-2028)
  • Table 281. United Kingdom Chronic Obstructive Pulmonary Disorder, by Application USD Million (2023-2028)
  • Table 282. United Kingdom Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2023-2028)
  • Table 283. United Kingdom Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2023-2028)
  • Table 284. United Kingdom Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2023-2028)
  • Table 285. Netherlands Chronic Obstructive Pulmonary Disorder, by Type USD Million (2023-2028)
  • Table 286. Netherlands Chronic Obstructive Pulmonary Disorder, by Application USD Million (2023-2028)
  • Table 287. Netherlands Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2023-2028)
  • Table 288. Netherlands Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2023-2028)
  • Table 289. Netherlands Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2023-2028)
  • Table 290. Rest of Europe Chronic Obstructive Pulmonary Disorder, by Type USD Million (2023-2028)
  • Table 291. Rest of Europe Chronic Obstructive Pulmonary Disorder, by Application USD Million (2023-2028)
  • Table 292. Rest of Europe Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2023-2028)
  • Table 293. Rest of Europe Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2023-2028)
  • Table 294. Rest of Europe Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2023-2028)
  • Table 295. MEA Chronic Obstructive Pulmonary Disorder, by Country USD Million (2023-2028)
  • Table 296. MEA Chronic Obstructive Pulmonary Disorder, by Type USD Million (2023-2028)
  • Table 297. MEA Chronic Obstructive Pulmonary Disorder, by Application USD Million (2023-2028)
  • Table 298. MEA Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2023-2028)
  • Table 299. MEA Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2023-2028)
  • Table 300. MEA Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2023-2028)
  • Table 301. Middle East Chronic Obstructive Pulmonary Disorder, by Type USD Million (2023-2028)
  • Table 302. Middle East Chronic Obstructive Pulmonary Disorder, by Application USD Million (2023-2028)
  • Table 303. Middle East Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2023-2028)
  • Table 304. Middle East Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2023-2028)
  • Table 305. Middle East Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2023-2028)
  • Table 306. Africa Chronic Obstructive Pulmonary Disorder, by Type USD Million (2023-2028)
  • Table 307. Africa Chronic Obstructive Pulmonary Disorder, by Application USD Million (2023-2028)
  • Table 308. Africa Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2023-2028)
  • Table 309. Africa Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2023-2028)
  • Table 310. Africa Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2023-2028)
  • Table 311. North America Chronic Obstructive Pulmonary Disorder, by Country USD Million (2023-2028)
  • Table 312. North America Chronic Obstructive Pulmonary Disorder, by Type USD Million (2023-2028)
  • Table 313. North America Chronic Obstructive Pulmonary Disorder, by Application USD Million (2023-2028)
  • Table 314. North America Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2023-2028)
  • Table 315. North America Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2023-2028)
  • Table 316. North America Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2023-2028)
  • Table 317. United States Chronic Obstructive Pulmonary Disorder, by Type USD Million (2023-2028)
  • Table 318. United States Chronic Obstructive Pulmonary Disorder, by Application USD Million (2023-2028)
  • Table 319. United States Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2023-2028)
  • Table 320. United States Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2023-2028)
  • Table 321. United States Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2023-2028)
  • Table 322. Canada Chronic Obstructive Pulmonary Disorder, by Type USD Million (2023-2028)
  • Table 323. Canada Chronic Obstructive Pulmonary Disorder, by Application USD Million (2023-2028)
  • Table 324. Canada Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2023-2028)
  • Table 325. Canada Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2023-2028)
  • Table 326. Canada Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2023-2028)
  • Table 327. Mexico Chronic Obstructive Pulmonary Disorder, by Type USD Million (2023-2028)
  • Table 328. Mexico Chronic Obstructive Pulmonary Disorder, by Application USD Million (2023-2028)
  • Table 329. Mexico Chronic Obstructive Pulmonary Disorder, by Medication Type USD Million (2023-2028)
  • Table 330. Mexico Chronic Obstructive Pulmonary Disorder, by Treatment Type USD Million (2023-2028)
  • Table 331. Mexico Chronic Obstructive Pulmonary Disorder, by Diagnosis USD Million (2023-2028)
  • Table 332. Research Programs/Design for This Report
  • Table 333. Key Data Information from Secondary Sources
  • Table 334. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Chronic Obstructive Pulmonary Disorder: by Type USD Million (2017-2022)
  • Figure 5. Global Chronic Obstructive Pulmonary Disorder: by Application USD Million (2017-2022)
  • Figure 6. Global Chronic Obstructive Pulmonary Disorder: by Medication Type USD Million (2017-2022)
  • Figure 7. Global Chronic Obstructive Pulmonary Disorder: by Treatment Type USD Million (2017-2022)
  • Figure 8. Global Chronic Obstructive Pulmonary Disorder: by Diagnosis USD Million (2017-2022)
  • Figure 9. South America Chronic Obstructive Pulmonary Disorder Share (%), by Country
  • Figure 10. Asia Pacific Chronic Obstructive Pulmonary Disorder Share (%), by Country
  • Figure 11. Europe Chronic Obstructive Pulmonary Disorder Share (%), by Country
  • Figure 12. MEA Chronic Obstructive Pulmonary Disorder Share (%), by Country
  • Figure 13. North America Chronic Obstructive Pulmonary Disorder Share (%), by Country
  • Figure 14. Global Chronic Obstructive Pulmonary Disorder share by Players 2022 (%)
  • Figure 15. Global Chronic Obstructive Pulmonary Disorder share by Players (Top 3) 2022(%)
  • Figure 16. Global Chronic Obstructive Pulmonary Disorder share by Players (Top 5) 2022(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 19. AstraZeneca (United Kingdom) Revenue: by Geography 2022
  • Figure 20. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 21. Boehringer Ingelheim (Germany) Revenue: by Geography 2022
  • Figure 22. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2022
  • Figure 24. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 26. Teva Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 27. Teva Pharmaceuticals (Israel) Revenue: by Geography 2022
  • Figure 28. Ache Laboratorios Farmaceuticos (Brazil) Revenue, Net Income and Gross profit
  • Figure 29. Ache Laboratorios Farmaceuticos (Brazil) Revenue: by Geography 2022
  • Figure 30. Sunovion Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Sunovion Pharmaceuticals Inc. (United States) Revenue: by Geography 2022
  • Figure 32. CHIESI Farmaceutici S.p.A. (Italy) Revenue, Net Income and Gross profit
  • Figure 33. CHIESI Farmaceutici S.p.A. (Italy) Revenue: by Geography 2022
  • Figure 34. Almirall (Spain) Revenue, Net Income and Gross profit
  • Figure 35. Almirall (Spain) Revenue: by Geography 2022
  • Figure 36. Aquinox Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 37. Aquinox Pharmaceuticals (United States) Revenue: by Geography 2022
  • Figure 38. Orion Corporation (Finland) Revenue, Net Income and Gross profit
  • Figure 39. Orion Corporation (Finland) Revenue: by Geography 2022
  • Figure 40. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 41. Mylan N.V. (United States) Revenue: by Geography 2022
  • Figure 42. Ario Pharma (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 43. Ario Pharma (United Kingdom) Revenue: by Geography 2022
  • Figure 44. Global Chronic Obstructive Pulmonary Disorder: by Type USD Million (2023-2028)
  • Figure 45. Global Chronic Obstructive Pulmonary Disorder: by Application USD Million (2023-2028)
  • Figure 46. Global Chronic Obstructive Pulmonary Disorder: by Medication Type USD Million (2023-2028)
  • Figure 47. Global Chronic Obstructive Pulmonary Disorder: by Treatment Type USD Million (2023-2028)
  • Figure 48. Global Chronic Obstructive Pulmonary Disorder: by Diagnosis USD Million (2023-2028)
  • Figure 49. South America Chronic Obstructive Pulmonary Disorder Share (%), by Country
  • Figure 50. Asia Pacific Chronic Obstructive Pulmonary Disorder Share (%), by Country
  • Figure 51. Europe Chronic Obstructive Pulmonary Disorder Share (%), by Country
  • Figure 52. MEA Chronic Obstructive Pulmonary Disorder Share (%), by Country
  • Figure 53. North America Chronic Obstructive Pulmonary Disorder Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AstraZeneca (United Kingdom)
  • Boehringer Ingelheim (Germany)
  • GlaxoSmithKline plc (United Kingdom)
  • Novartis AG (Switzerland)
  • Teva Pharmaceuticals (Israel)
  • Ache Laboratorios Farmaceuticos (Brazil)
  • Sunovion Pharmaceuticals Inc. (United States)
  • CHIESI Farmaceutici S.p.A. (Italy)
  • Almirall (Spain)
  • Aquinox Pharmaceuticals (United States)
  • Orion Corporation (Finland)
  • Mylan N.V. (United States)
  • Ario Pharma (United Kingdom)
Additional players considered in the study are as follows:
Odan Laboratories (Canada) , Astellas Pharma (Japan) , BioMarck Pharmaceuticals (United States)
Select User Access Type

Key Highlights of Report


May 2023 237 Pages 97 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Chronic Obstructive Pulmonary Disorder Quantitative research analysis
Global Chronic Obstructive Pulmonary Disorder Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The prominent players of Global Chronic Obstructive Pulmonary Disorder market are AstraZeneca (United Kingdom), Boehringer Ingelheim (Germany), GlaxoSmithKline plc (United Kingdom), Novartis AG (Switzerland), Teva Pharmaceuticals (Israel), Ache Laboratorios Farmaceuticos (Brazil), Sunovion Pharmaceuticals Inc. (United States), CHIESI Farmaceutici S.p.A. (Italy), Almirall (Spain), Aquinox Pharmaceuticals (United States), Orion Corporation (Finland), Mylan N.V. (United States) and Ario Pharma (United Kingdom).
In this highly competitive & fast evolving Chronic Obstructive Pulmonary Disorder industry, the top strategic priorities would remain consistent like innovation, R&D, and M&A.
Hospital Pharmacies, Retail Pharmacies and Online Pharmacies are the potential customers of Chronic Obstructive Pulmonary Disorder industry.

Know More About Global Chronic Obstructive Pulmonary Disorder Report?

Have a Query? Click Here

Other Related Reports

Camellia Oil Comprehensive Study by Type (Extra Virgin camellia Oil, Pure camellia Oil, Pomace camellia Oil), Application (Food, Cosmetics, Pharmaceuticals, Chemical Industry), Distribution Channel (...
$ 3500
HIV Diagnosis Comprehensive Study by Type (Consumables (Assays and Kits & Reagents, and other Consumables), Instruments, Software & Services), Test Type (Antibody Tests (HIV-1 Screening Tests, HIV-1 ...
$ 3750
Vitiligo Drug Comprehensive Study by Type (ARN-4079, ATI-50001, AX-1602, Ruxolitinib Phosphate, VLRX-001, Others), Application (Clinic, Hospital, Others), Route of Administration (Oral, Topical), Dis...
$ 3750
Nicotine Addiction Treatment Comprehensive Study by Type (OMS-527, AT-1001, CTDP-002, EORA-101, URB-694, Others), Application (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacies, Me...
$ 3750
Preventable Vaccines Comprehensive Study by Type (Live/Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Others), Application (Pneumococcal, Poliovirus, Hepatitis, Influen...
$ 3650
Influenza Medication Comprehensive Study by Type (Zanamivir, Oseltamivir phosphate, Peramivir, Other Influenza Medication), Application (Hospitals, Clinics, Pharmacies, Others), Treatment Type (Medic...
$ 3450